• Tenaya highlighted 2026 catalysts to advance TN-201 and TN-401 toward pivotal-study planning, with regulatory endpoint and design updates expected in 2H 2026.
• TN-201 MyPEAK-1 interim data showed improvement across biomarkers, hypertrophy measures, symptom scores, and functional capacity, with durability out to 2 years in Cohort 1.
• All evaluable TN-201 patients achieved LVMI reductions; Cohort 2 showed declines as early as week 26, including -21% and -25% in two patients.
• TN-201 safety profile remained consistent, with mostly mild, transient, reversible adverse events; the most common were asymptomatic liver enzyme elevations.
• TN-301 HDAC6 inhibitor completed a Phase 1 healthy-volunteer trial; Tenaya aims to move into Phase 2 to establish proof-of-activity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.